San Francisco, June 21st, 2017 – Recardio Inc. today announced that it has appointed its newly formed Scientific Advisory Board, reflecting the company’s entering the clinical phase 2 development in 2017.
Recardio receives FDA Clearance
San Francisco, March 27th, 2017 – Recardio Inc. Receives FDA Clearance of IND in Regenerative Therapy Program.
Recardio at BIO CEO & Investor Conference
San Francisco, Feb. 13, 2017 – Recardio, is participating in the BIO CEO & Investor Conference.Read More
Recardio Appoints New Management Positions
San Francisco, Jan. 23, 2017 – Recardio named Angela Birchler as Chief Manufacturing Officer and Dave Reed as Vice President of CMC.
Recardio has today Presented at TCT Conference in Washington
San Francisco, Oct. 29, 2016 – Recardio, announced that its scientific presentation on dutogliptin was accepted and will be presented by Darrell Nix, CSO, at the TCT conference in Washington.Read More